JP2018518974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518974A5 JP2018518974A5 JP2017567178A JP2017567178A JP2018518974A5 JP 2018518974 A5 JP2018518974 A5 JP 2018518974A5 JP 2017567178 A JP2017567178 A JP 2017567178A JP 2017567178 A JP2017567178 A JP 2017567178A JP 2018518974 A5 JP2018518974 A5 JP 2018518974A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antigen recognition
- receptor
- cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 32
- 102000036639 antigens Human genes 0.000 claims 32
- 108091007433 antigens Proteins 0.000 claims 32
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 19
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 17
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 17
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 14
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 13
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 13
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 13
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 13
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 12
- 102000010956 Glypican Human genes 0.000 claims 12
- 108050001154 Glypican Proteins 0.000 claims 12
- 108050007237 Glypican-3 Proteins 0.000 claims 12
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 12
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 12
- -1 LeY Proteins 0.000 claims 12
- 102100035721 Syndecan-1 Human genes 0.000 claims 12
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 12
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 12
- 230000000139 costimulatory effect Effects 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 11
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 11
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 11
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 11
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 10
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 10
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 10
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 10
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 10
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 10
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 10
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 10
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 10
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 7
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 7
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 6
- 102100022749 Aminopeptidase N Human genes 0.000 claims 6
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 6
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 6
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 6
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 6
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 6
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 6
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 6
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims 6
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 6
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 6
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 6
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 6
- 102100032999 Integrin beta-3 Human genes 0.000 claims 6
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 6
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 6
- 102100025136 Macrosialin Human genes 0.000 claims 6
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 6
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 6
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 5
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 3
- 108010065524 CD52 Antigen Proteins 0.000 claims 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 3
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 3
- 108010065805 Interleukin-12 Proteins 0.000 claims 3
- 108090000172 Interleukin-15 Proteins 0.000 claims 3
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 claims 3
- 101710107699 Interleukin-15 receptor subunit alpha Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 108010002586 Interleukin-7 Proteins 0.000 claims 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 108010074108 interleukin-21 Proteins 0.000 claims 3
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
- 208000001715 Osteoblastoma Diseases 0.000 claims 1
- 208000002774 Paraproteinemias Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021167360A JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2023053851A JP7502515B2 (ja) | 2015-06-25 | 2023-03-29 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2024092213A JP2024116259A (ja) | 2015-06-25 | 2024-06-06 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562184321P | 2015-06-25 | 2015-06-25 | |
| US62/184,321 | 2015-06-25 | ||
| US201562235840P | 2015-10-01 | 2015-10-01 | |
| US62/235,840 | 2015-10-01 | ||
| US201562244435P | 2015-10-21 | 2015-10-21 | |
| US62/244,435 | 2015-10-21 | ||
| PCT/US2016/039306 WO2016210293A1 (en) | 2015-06-25 | 2016-06-24 | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167360A Division JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518974A JP2018518974A (ja) | 2018-07-19 |
| JP2018518974A5 true JP2018518974A5 (OSRAM) | 2019-07-18 |
| JP6961497B2 JP6961497B2 (ja) | 2021-11-05 |
Family
ID=57586695
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567178A Active JP6961497B2 (ja) | 2015-06-25 | 2016-06-24 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2021167360A Active JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2023053851A Active JP7502515B2 (ja) | 2015-06-25 | 2023-03-29 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2024092213A Pending JP2024116259A (ja) | 2015-06-25 | 2024-06-06 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167360A Active JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2023053851A Active JP7502515B2 (ja) | 2015-06-25 | 2023-03-29 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2024092213A Pending JP2024116259A (ja) | 2015-06-25 | 2024-06-06 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11655452B2 (OSRAM) |
| EP (1) | EP3313872A4 (OSRAM) |
| JP (4) | JP6961497B2 (OSRAM) |
| KR (1) | KR20180021137A (OSRAM) |
| CN (2) | CN115058395B (OSRAM) |
| AU (3) | AU2016283102B2 (OSRAM) |
| CA (1) | CA2990177A1 (OSRAM) |
| IL (2) | IL287718B2 (OSRAM) |
| SG (1) | SG10201913682QA (OSRAM) |
| TW (2) | TWI833684B (OSRAM) |
| WO (1) | WO2016210293A1 (OSRAM) |
Families Citing this family (165)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| CA3224507A1 (en) | 2014-12-24 | 2016-06-30 | Autolus Limited | Cell co-expressing chimeric antigen receptors binding cd19 and cd22 |
| JP6961490B2 (ja) | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| WO2017222593A1 (en) * | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| CN115058395B (zh) * | 2015-06-25 | 2025-07-18 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| EP3339320A4 (en) | 2015-08-17 | 2019-01-23 | Seoul National University R&DB Foundation | CHIMERIC ANTIBODY RECEPTOR WITH AN ANTI-COTININ ANTIBODY BELARED AND USE THEREOF |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
| US11078481B1 (en) | 2016-08-03 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for screening for cancer targets |
| EP3494132A4 (en) | 2016-08-03 | 2020-03-18 | Washington University | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| JP7160482B2 (ja) * | 2016-09-02 | 2022-10-25 | レンティジェン・テクノロジー・インコーポレイテッド | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2019535262A (ja) * | 2016-11-11 | 2019-12-12 | オートラス リミテッド | キメラ抗原受容体 |
| AU2017363311A1 (en) * | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| US10799536B2 (en) | 2016-12-09 | 2020-10-13 | Onk Therapeutics Limited | Method of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38 |
| JP7033601B2 (ja) | 2017-01-05 | 2022-03-10 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | 抗コチニンキメラ抗原受容体を発現するナチュラルキラー細胞 |
| WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| CA3051866A1 (en) * | 2017-02-01 | 2018-08-09 | Nant Holdings Ip, Llc | Calreticulin-mediated cancer treatment |
| CA3055832A1 (en) * | 2017-03-10 | 2018-09-13 | The Medical College Of Wisconsin, Inc. | Riboswitch modulated gene therapy for retinal diseases |
| CN117959418A (zh) * | 2017-03-13 | 2024-05-03 | 波赛达治疗公司 | 用于选择性消除和替换造血干细胞的组合物和方法 |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| SG11201908337VA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| ES2905377T3 (es) * | 2017-04-18 | 2022-04-08 | Autolus Ltd | Célula |
| CN110753555A (zh) * | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| CN110650975B (zh) * | 2017-05-15 | 2024-04-05 | 美国卫生和人力服务部 | 双顺反子嵌合抗原受体及其用途 |
| CN110831970B (zh) | 2017-06-02 | 2024-12-17 | 辉瑞公司 | 靶向flt3的嵌合抗原受体 |
| EP3635099A4 (en) * | 2017-06-07 | 2021-02-24 | The General Hospital Corporation | T-CELLS WITH EXPRESSION OF A CHIMERIC ANTIGEN RECEPTOR |
| CA3067211A1 (en) | 2017-06-12 | 2018-12-20 | Obsidian Therapeutics, Inc. | Pde5 compositions and methods for immunotherapy |
| CN118853581A (zh) | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| WO2019006436A1 (en) | 2017-06-30 | 2019-01-03 | Inscripta, Inc. | METHODS, MODULES, INSTRUMENTS AND SYSTEMS FOR AUTOMATED CELL PROCESSING |
| CN111315872A (zh) | 2017-06-30 | 2020-06-19 | 纪念斯隆-凯特林癌症中心 | 用于癌症的过继性细胞疗法的组合物和方法 |
| CA3068636A1 (en) | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| US12496310B2 (en) | 2017-06-30 | 2025-12-16 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy |
| CA3068841A1 (en) | 2017-07-03 | 2019-01-10 | Torque Therapeutics, Inc. | Fusion molecules targeting immune regulatory cells and uses thereof |
| WO2019018525A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CHIMERIC ANTIGENIC RECEPTORS BINDING TO CD123 |
| JP2021520184A (ja) * | 2017-09-29 | 2021-08-19 | ナントセル，インコーポレイテッド | Ｃｄ１ｄ及びｔｃｒ−ｎｋｔ細胞 |
| JP7710644B2 (ja) * | 2017-10-12 | 2025-07-22 | アイセル・ジーン・セラピューティクス・インコーポレイテッド | 複数の抗原を標的とするｃｏｍｐｏｕｎｄキメラ抗原受容体（ｃＣＡＲ）の組成物およびその使用方法 |
| KR20200086278A (ko) | 2017-10-18 | 2020-07-16 | 노파르티스 아게 | 선택적 단백질 분해를 위한 조성물 및 방법 |
| EP3703735A1 (en) * | 2017-11-01 | 2020-09-09 | Nantkwest, Inc. | Nk-92 cells to stimulate anti-cancer vaccine |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| TW201922774A (zh) | 2017-11-15 | 2019-06-16 | 瑞士商諾華公司 | 標靶bcma嵌合抗原受體、標靶cd19嵌合抗原受體及組合療法 |
| AU2018375738A1 (en) | 2017-11-30 | 2020-06-11 | Novartis Ag | BCMA-targeting chimeric antigen receptor, and uses thereof |
| CN111587254B (zh) * | 2017-12-05 | 2025-02-25 | 特拉维夫医疗中心医学研究基础设施及卫生服务基金 | 包含抗cd38和抗cd138嵌合抗原受体的t-细胞及其用途 |
| EP3720882A4 (en) | 2017-12-05 | 2021-10-27 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | T LYMPHOCYTES INCLUDING TWO DIFFERENT ANTIGENIC CHEMERICAL RECEPTORS AND THEIR USES |
| WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CN111918661A (zh) | 2018-02-21 | 2020-11-10 | 得克萨斯大学体系董事会 | 用于活化和扩增自然杀伤细胞的方法及其用途 |
| MX2020008803A (es) | 2018-02-23 | 2021-01-15 | H Lee Moffitt Cancer Ct & Res | Receptores de antígenos quiméricos que se unen a cd83. |
| US10780120B2 (en) | 2018-03-06 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| EP3773588A4 (en) * | 2018-04-09 | 2022-01-19 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASES |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US10557216B2 (en) | 2018-04-24 | 2020-02-11 | Inscripta, Inc. | Automated instrumentation for production of T-cell receptor peptide libraries |
| US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| EP3784272A1 (en) * | 2018-04-27 | 2021-03-03 | CRISPR Therapeutics AG | Anti-bcma car-t-cells for plasma cell depletion |
| JP7599205B2 (ja) * | 2018-06-01 | 2024-12-13 | アンヘレス セラピューティクス インコーポレイテッド | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
| CN110577605A (zh) * | 2018-06-11 | 2019-12-17 | 浙江启新生物技术有限公司 | 一种靶向多发性骨髓瘤多种抗原的嵌合抗原受体t（car-t）细胞的构建方法及其应用 |
| CN110305847B (zh) * | 2018-07-27 | 2021-05-18 | 赛诺生（深圳）基因产业发展有限公司 | 一种用于治疗肿瘤的基因工程细胞 |
| CA3107119A1 (en) * | 2018-07-31 | 2020-02-06 | Washington University | Use of interleukin-7 and chimeric antigen receptor (car)-bearing immune effector cells for treating tumor |
| IL296050B2 (en) * | 2018-08-01 | 2024-12-01 | Immunitybio Inc | A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies |
| WO2020033585A1 (en) * | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Methods for combinatorial screening and use of therapeutic targets thereof |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| US10533152B1 (en) | 2018-08-14 | 2020-01-14 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| CN109306016B (zh) * | 2018-08-15 | 2021-10-22 | 华东师范大学 | 共表达细胞因子il-7的nkg2d-car-t细胞及其用途 |
| KR102839381B1 (ko) | 2018-08-29 | 2025-07-28 | 내셔널 유니버시티 오브 싱가포르 | 유전적으로 변형된 면역 세포의 생존 및 확장을 특이적으로 자극하는 방법 |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| SG11202101825QA (en) | 2018-08-31 | 2021-03-30 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| CN112955172A (zh) * | 2018-09-17 | 2021-06-11 | 美国卫生和人力服务部 | 靶向cd19和cd20的双顺反子嵌合抗原受体及其用途 |
| JP2022501067A (ja) * | 2018-09-26 | 2022-01-06 | 上海恒潤達生生物科技有限公司Hrain Biotechnology Co., Ltd. | Ｂｃｍａ及びｃｄ１９を標的とするキメラ抗原受容体、並びにその使用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US20210338729A1 (en) * | 2018-10-12 | 2021-11-04 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF |
| US10993967B2 (en) * | 2018-10-17 | 2021-05-04 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
| US11077143B2 (en) | 2018-10-31 | 2021-08-03 | Nantkwest Inc. | Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| KR20250024868A (ko) | 2018-10-31 | 2025-02-19 | 난트퀘스트, 인크. | Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거 |
| EP3873500A4 (en) | 2018-10-31 | 2023-01-11 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| CA3117419A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| WO2020106621A1 (en) * | 2018-11-19 | 2020-05-28 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| JP7584414B2 (ja) * | 2018-11-26 | 2024-11-15 | ンカルタ・インコーポレイテッド | 複数の免疫細胞タイプの同時増殖のための方法、関連する組成物および癌免疫療法におけるそれらの使用 |
| WO2020112669A1 (en) * | 2018-11-26 | 2020-06-04 | Nantkwest, Inc. | Il-2 dependent nk-92 cells with stable fc receptor expression |
| MX2021006968A (es) | 2018-12-12 | 2021-10-13 | Kite Pharma Inc | Antígeno quimérico y receptores de las células t, y métodos de uso. |
| JP2022524178A (ja) * | 2019-01-07 | 2022-04-28 | セルリス パルティシパソエス リミターダ | タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法 |
| AU2020226401A1 (en) * | 2019-02-18 | 2021-10-14 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| SG11202107825WA (en) | 2019-02-25 | 2021-09-29 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US12018061B2 (en) * | 2019-03-08 | 2024-06-25 | St Phi Therapeutics Co., Ltd. | Chimeric endocytic receptors and method of use thereof |
| WO2020190902A1 (en) * | 2019-03-19 | 2020-09-24 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptors with enhanced tumor infiltration |
| US20220088073A1 (en) * | 2019-03-19 | 2022-03-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric antigen receptors with enhanced tumor infiltration |
| WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| EP3947691A4 (en) | 2019-03-25 | 2022-12-14 | Inscripta, Inc. | SIMULTANEOUS MULTIPLEX GENOME EDITING IN A YEAST |
| US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| MX2021013117A (es) * | 2019-04-26 | 2022-02-11 | Aleta Biotherapeutics Inc | Composiciones y metodos para el tratamiento del cancer. |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| US12023354B2 (en) * | 2019-05-31 | 2024-07-02 | Case Western Reserve University | Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells |
| US10837021B1 (en) | 2019-06-06 | 2020-11-17 | Inscripta, Inc. | Curing for recursive nucleic acid-guided cell editing |
| EP3980453A4 (en) * | 2019-06-07 | 2023-07-05 | The Trustees of the University of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| AU2020315796A1 (en) * | 2019-07-19 | 2022-02-24 | Memorial Hospital For Cancer And Allied Diseases | Fusion polypeptide for immunotherapy |
| CN110452294B (zh) * | 2019-08-06 | 2020-08-07 | 复旦大学 | 五种铰链区及其嵌合抗原受体和免疫细胞 |
| WO2021033089A1 (en) | 2019-08-16 | 2021-02-25 | Janssen Biotech, Inc. | Therapeutic immune cells with improved function and methods for making the same |
| CA3149543A1 (en) * | 2019-08-27 | 2021-03-04 | Donald M. O'rourke | Synthetic cars to treat il13r.alpha.2 positive human and canine tumors |
| CN112442509A (zh) * | 2019-08-29 | 2021-03-05 | 爱博赛特生物治疗公司 | Cd19-cd20双特异性和双通道car-t及其使用方法 |
| JP7692897B2 (ja) | 2019-09-10 | 2025-06-16 | オブシディアン セラピューティクス， インコーポレイテッド | 調節可能な制御のためのｃａ２－ｉｌ１５融合タンパク質 |
| WO2021055349A1 (en) * | 2019-09-18 | 2021-03-25 | Board Of Regents, The University Of Texas System | A method of engineering natural killer-cells to target bcma-positive tumors |
| US11203762B2 (en) | 2019-11-19 | 2021-12-21 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
| AR120566A1 (es) * | 2019-11-26 | 2022-02-23 | Novartis Ag | Receptores de antígeno quiméricos y sus usos |
| BR112022009679A2 (pt) | 2019-11-26 | 2022-08-09 | Novartis Ag | Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos |
| IL293552A (en) * | 2019-12-05 | 2022-08-01 | Vycellix Inc | Modulators of the immune escape mechanism for universal cell therapy |
| EP4069851A4 (en) | 2019-12-18 | 2023-11-22 | Inscripta, Inc. | Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells |
| IL294518A (en) * | 2020-01-13 | 2022-09-01 | Nkarta Inc | Bcma-directed cellular immunotherapy compositions and methods |
| EP4093767A1 (en) * | 2020-01-22 | 2022-11-30 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor |
| KR20220133257A (ko) | 2020-01-27 | 2022-10-04 | 인스크립타 인코포레이티드 | 전기천공 모듈 및 기구 |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| US20210238535A1 (en) * | 2020-02-02 | 2021-08-05 | Inscripta, Inc. | Automated production of car-expressing cells |
| JP2023512657A (ja) * | 2020-02-05 | 2023-03-28 | ワシントン・ユニバーシティ | Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| KR20220147109A (ko) | 2020-02-27 | 2022-11-02 | 노파르티스 아게 | 키메라 항원 수용체 발현 세포의 제조 방법 |
| AR121461A1 (es) | 2020-02-27 | 2022-06-08 | Novartis Ag | Métodos para la fabricación de células que expresan el receptor de antígeno quimérico |
| WO2022074464A2 (en) | 2020-03-05 | 2022-04-14 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
| US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
| WO2021223705A1 (en) * | 2020-05-06 | 2021-11-11 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| PE20230494A1 (es) | 2020-05-08 | 2023-03-23 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas |
| US20230227525A1 (en) * | 2020-05-08 | 2023-07-20 | Smt Bio Co., Ltd. | Chimeric antigen receptor for treatment of cancer |
| US11787841B2 (en) | 2020-05-19 | 2023-10-17 | Inscripta, Inc. | Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli |
| EP4157863A4 (en) * | 2020-05-29 | 2024-10-02 | iCell Gene Therapeutics, LLC | ENGINEERED IMMUNE CELLS, COMPOSITIONS AND RELATED METHODS |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| IL298693A (en) * | 2020-06-04 | 2023-02-01 | Carisma Therapeutics Inc | New structures for chimeric antigen receptors |
| AU2021288224A1 (en) | 2020-06-11 | 2023-01-05 | Novartis Ag | ZBTB32 inhibitors and uses thereof |
| TW202227124A (zh) | 2020-08-21 | 2022-07-16 | 瑞士商諾華公司 | 用於體內產生ｃａｒ表現細胞的組成物和方法 |
| GB202013477D0 (en) * | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| WO2022052913A1 (en) * | 2020-09-08 | 2022-03-17 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| US11299731B1 (en) | 2020-09-15 | 2022-04-12 | Inscripta, Inc. | CRISPR editing to embed nucleic acid landing pads into genomes of live cells |
| WO2022076256A1 (en) * | 2020-10-05 | 2022-04-14 | Icell Gene Therapeutics Llc | Engineered immune cells for immunotherapy using endoplasmic retention techniques |
| US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
| US20240000838A1 (en) * | 2020-11-30 | 2024-01-04 | Simcere Innovation, Inc. | Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy |
| TW202233662A (zh) * | 2020-12-31 | 2022-09-01 | 大陸商亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫細胞中的應用 |
| WO2022146497A1 (en) | 2021-01-04 | 2022-07-07 | Inscripta, Inc. | Mad nucleases |
| WO2022150269A1 (en) | 2021-01-07 | 2022-07-14 | Inscripta, Inc. | Mad nucleases |
| CN112778427B (zh) * | 2021-01-29 | 2022-03-15 | 武汉思安医疗技术有限公司 | 双特异性cs1-bcma car-t细胞及其应用 |
| US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
| CN112698037B (zh) * | 2021-03-25 | 2021-06-25 | 北京积水潭医院 | 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用 |
| US20240384293A1 (en) | 2021-04-27 | 2024-11-21 | Novartis Ag | Viral vector production system |
| AU2022330406A1 (en) | 2021-08-20 | 2024-03-07 | Novartis Ag | Methods of making chimeric antigen receptor–expressing cells |
| CN114835820B (zh) * | 2022-04-14 | 2023-01-06 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 用于基因改造的多能干细胞及、自然杀伤细胞的嵌合型Fc受体 |
| CN116574194A (zh) * | 2022-06-02 | 2023-08-11 | 深圳普瑞金生物药业股份有限公司 | 嵌合抗原受体及其用途 |
| CN115232217B (zh) * | 2022-07-04 | 2023-06-06 | 深圳市先康达生命科学有限公司 | 一种SynNotch结构及其应用 |
| GB202209920D0 (en) * | 2022-07-06 | 2022-08-17 | Autolus Ltd | Cell |
| AU2023369684A1 (en) | 2022-10-26 | 2025-04-17 | Novartis Ag | Lentiviral formulations |
| KR20240081499A (ko) * | 2022-11-11 | 2024-06-10 | 주식회사 유씨아이테라퓨틱스 | 유전자 조작된 세포 및 이의 용도 |
| KR20240072334A (ko) * | 2022-11-11 | 2024-05-24 | 주식회사 유씨아이테라퓨틱스 | 유전자 조작된 세포 및 이의 용도 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| EP4574838A1 (en) | 2023-12-21 | 2025-06-25 | Vilnius University | Chimeric antigen receptor (car) with enhanced recruitment of signaling partners |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US20030147865A1 (en) | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
| US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| US20040265315A1 (en) | 2002-09-05 | 2004-12-30 | Christine Dingivan | Methods of preventing or treating T cell malignancies by administering CD2 antagonists |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2005108415A2 (en) | 2004-04-30 | 2005-11-17 | Biogen Idec Ma Inc. | Membrane associated molecules |
| US20050277587A1 (en) | 2004-06-10 | 2005-12-15 | Academia Sinica | CD7 as biomarker and therapeutic target for psoriasis |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| AU2007239095B2 (en) | 2006-01-09 | 2012-05-03 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
| CN101501498A (zh) | 2006-06-12 | 2009-08-05 | 森托科尔公司 | 根据rantes代表物水平检测il-16活性和对il-16活性的调节的方法 |
| BRPI0716680A2 (pt) | 2006-11-02 | 2013-09-24 | Daniel J Capon | "composto, multÍmero, composiÇço, mÉtodo de afetar a atividade de um alvo, complexo, processo de produÇço do composto, mÉtodo de produÇço de um extensço de aminoÁcidos consecutivos, processo de produÇço de uma extensço de aminoacidos consecutivos , processo para a produÇço de um composto , mÉtodo de produÇço de uma proteina e polipeptÍdeo" |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| US9206440B2 (en) | 2009-01-23 | 2015-12-08 | Roger Williams Hospital | Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same |
| EP2429584A4 (en) | 2009-05-13 | 2013-02-20 | Genzyme Corp | TREATMENT PROCEDURE AND COMPOSITIONS |
| EP2429583A4 (en) | 2009-05-13 | 2013-10-16 | Genzyme Corp | METHOD AND COMPOSITIONS FOR LUPUS TREATMENT |
| EP2325322A1 (en) | 2009-11-23 | 2011-05-25 | 4-Antibody AG | Retroviral vector particles and methods for their generation and use |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3693017A1 (en) | 2010-12-14 | 2020-08-12 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| US8785190B2 (en) | 2011-04-06 | 2014-07-22 | Sanbio, Inc. | Methods and compositions for modulating peripheral immune function |
| KR101681818B1 (ko) | 2011-08-23 | 2016-12-01 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| SG11201404285VA (en) | 2012-02-22 | 2014-10-30 | Univ Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| CA2878856A1 (en) * | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating car t cells |
| CN104853766A (zh) | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP2953475B1 (en) * | 2013-02-06 | 2019-07-03 | Celgene Corporation | Modified t lymphocytes having improved specificity |
| KR102064230B1 (ko) | 2013-02-15 | 2020-01-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| WO2014130635A1 (en) * | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| US9745368B2 (en) * | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| BR112015028387B1 (pt) | 2013-05-13 | 2023-04-11 | Cellectis | Receptor antigênico quimérico específico para cd19, polinucleotídeo, vetor de expressão, método in vitro para manipulação e uso de uma célula imune |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| EP3659622A1 (en) | 2013-08-08 | 2020-06-03 | Cytune Pharma | Combined pharmaceutical composition |
| AU2014342020C1 (en) | 2013-10-31 | 2019-09-05 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof |
| MY176522A (en) | 2013-11-04 | 2020-08-13 | Ichnos Sciences SA | Production of t cell retargeting hetero-dimeric immunoglobulins |
| MX373687B (es) | 2013-11-21 | 2020-07-07 | Ucl Business Ltd | Célula natural (nk) |
| ES2963718T3 (es) | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
| EP3102236A4 (en) | 2014-02-05 | 2017-08-30 | The University of Chicago | Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants |
| PT3105317T (pt) | 2014-02-14 | 2019-02-27 | Cellectis | Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas |
| KR102463529B1 (ko) | 2014-04-10 | 2022-11-07 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 약물 관련 트랜스진 발현 |
| US10301370B2 (en) | 2014-05-02 | 2019-05-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor T cells |
| US10604740B2 (en) | 2014-05-14 | 2020-03-31 | Carsgen Therapeutics Limited | Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| ES2791248T3 (es) * | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| RU2764074C2 (ru) | 2014-08-28 | 2022-01-13 | Байоатла, Ллк | Условно активные химерные антигенные рецепторы для модифицированных т-клеток |
| CN107109368A (zh) * | 2014-10-07 | 2017-08-29 | 塞勒克提斯公司 | 用于调节car诱导的免疫细胞活性的方法 |
| CA3224507A1 (en) | 2014-12-24 | 2016-06-30 | Autolus Limited | Cell co-expressing chimeric antigen receptors binding cd19 and cd22 |
| KR102632082B1 (ko) * | 2015-02-27 | 2024-02-02 | 아이셀 진 테라퓨틱스 엘엘씨 | 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도 |
| JP6961490B2 (ja) * | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| US11173179B2 (en) * | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| US20190135894A1 (en) * | 2015-06-25 | 2019-05-09 | iCell Gene Therapeuticics LLC | COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2017222593A1 (en) * | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| US20220241327A1 (en) * | 2015-06-25 | 2022-08-04 | Icell Gene Therapeutics Llc | Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof |
| CN115058395B (zh) * | 2015-06-25 | 2025-07-18 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| CN105087495B (zh) * | 2015-08-21 | 2016-04-27 | 深圳市茵冠生物科技有限公司 | 双嵌合抗原受体修饰的t淋巴细胞及其制备方法 |
| GB201518817D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| WO2017112877A1 (en) * | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| CN118853581A (zh) * | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| JP7710644B2 (ja) * | 2017-10-12 | 2025-07-22 | アイセル・ジーン・セラピューティクス・インコーポレイテッド | 複数の抗原を標的とするｃｏｍｐｏｕｎｄキメラ抗原受容体（ｃＣＡＲ）の組成物およびその使用方法 |
| AU2018375738A1 (en) * | 2017-11-30 | 2020-06-11 | Novartis Ag | BCMA-targeting chimeric antigen receptor, and uses thereof |
-
2016
- 2016-06-24 CN CN202210523997.3A patent/CN115058395B/zh active Active
- 2016-06-24 IL IL287718A patent/IL287718B2/en unknown
- 2016-06-24 EP EP16815399.7A patent/EP3313872A4/en active Pending
- 2016-06-24 TW TW105120100A patent/TWI833684B/zh active
- 2016-06-24 CN CN201680036459.4A patent/CN107849112B/zh active Active
- 2016-06-24 SG SG10201913682QA patent/SG10201913682QA/en unknown
- 2016-06-24 WO PCT/US2016/039306 patent/WO2016210293A1/en not_active Ceased
- 2016-06-24 TW TW113103577A patent/TW202444897A/zh unknown
- 2016-06-24 KR KR1020187002389A patent/KR20180021137A/ko active Pending
- 2016-06-24 CA CA2990177A patent/CA2990177A1/en active Pending
- 2016-06-24 AU AU2016283102A patent/AU2016283102B2/en active Active
- 2016-06-24 JP JP2017567178A patent/JP6961497B2/ja active Active
- 2016-06-24 US US15/739,596 patent/US11655452B2/en active Active
-
2017
- 2017-12-19 IL IL256410A patent/IL256410B/en unknown
-
2021
- 2021-05-28 AU AU2021203481A patent/AU2021203481B2/en active Active
- 2021-10-12 JP JP2021167360A patent/JP7254870B2/ja active Active
-
2023
- 2023-03-29 JP JP2023053851A patent/JP7502515B2/ja active Active
- 2023-09-22 AU AU2023233207A patent/AU2023233207B2/en active Active
-
2024
- 2024-06-06 JP JP2024092213A patent/JP2024116259A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518974A5 (OSRAM) | ||
| JP2019522973A5 (OSRAM) | ||
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| Klein et al. | Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines | |
| Verdon et al. | Cellular and molecular mechanisms of CD8+ T cell differentiation, dysfunction and exhaustion | |
| Kalos et al. | Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology | |
| Jacoby et al. | CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity | |
| Sadelain | CAR therapy: the CD19 paradigm | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Vinay et al. | 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy | |
| Ghasemi et al. | Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy | |
| Birkholz et al. | Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer | |
| JP2020074776A5 (OSRAM) | ||
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| RU2015109631A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2017513470A5 (OSRAM) | ||
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| JP2017515464A5 (OSRAM) | ||
| JP2020517259A5 (OSRAM) | ||
| RU2018118652A (ru) | Химерные конструкции антитело/т-клеточный рецептор и их применения | |
| RU2016143388A (ru) | Экспрессия трансгенов, регулируемая лекарственным средством | |
| JP2017506513A5 (OSRAM) | ||
| Ding et al. | Fusion proteins of NKG2D/NKG2DL in cancer immunotherapy | |
| JP2019528769A5 (OSRAM) | ||
| Opinto et al. | Hodgkin lymphoma: a special microenvironment |